Abbott gets FDA nod for Xience V

Abbott Laboratories has received U.S. Food and Drug Administration (FDA) clearance for its Xience V everolimus-eluting coronary stent system.

Xience V was cleared for the treatment of coronary artery disease. It will be launched in the U.S. immediately, according to the Abbott Park, IL-based company.

Related Reading

U.S. panel backs Abbott's drug-coated heart stent, December 3, 2007

Clots low with Abbott stent for 2 yrs: FDA staff, November 28, 2007

Abbott begins stent trial for cardiovascular disease, July 20, 2007

GE, Abbott break off acquisition, July 11, 2007

GE Healthcare to expand once more with $8 billion Abbott deal, January 19, 2007

Copyright © 2008 AuntMinnie.com

Page 1 of 374
Next Page